Prospera Financial Services Inc Buys 6,991 Shares of Merck & Co., Inc. $MRK

Prospera Financial Services Inc grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 6.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 117,517 shares of the company’s stock after purchasing an additional 6,991 shares during the period. Prospera Financial Services Inc’s holdings in Merck & Co., Inc. were worth $12,377,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $25,000. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. during the 3rd quarter worth approximately $31,000. High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Tucker Asset Management LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $34,000. Finally, Wealth Watch Advisors INC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $34,000. 76.07% of the stock is owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Sichuan Kelun-Biotech reported encouraging late-stage lung cancer data for a Keytruda combination, with the treatment beating Keytruda alone and improving confidence in Merck’s cancer pipeline. Kelun, Merck’s lung cancer combo improves survival in late-stage China trial
• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion for Keytruda plus Padcev as a perioperative treatment for certain bladder cancer patients, which could expand the drug pair’s commercial reach if formally approved. Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev
• Positive Sentiment: Additional coverage highlighted positive EU recommendations and trial momentum across Merck’s oncology portfolio, suggesting the company is building new growth drivers ahead of future Keytruda patent pressure. Merck stock jumps as Keytruda combo trials boost cancer pipeline
• Neutral Sentiment: Some commentary noted Gardasil sales remain weak due to soft demand in China and other markets, which is a reminder that Merck still has headwinds outside oncology. Will Weak Gardasil Sales Continue to Ail MRK’s Vaccines Sales in 2026?
• Neutral Sentiment: Merck’s recent run-up also reflects broader investor optimism after strong quarterly results and improving sentiment around its pipeline, rather than a single one-day event. Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Barclays assumed coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price on the stock. UBS Group boosted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, Wells Fargo & Company cut their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $122.55 on Friday. Merck & Co., Inc. has a twelve month low of $75.40 and a twelve month high of $125.14. The stock’s 50 day moving average price is $115.92 and its 200-day moving average price is $110.22. The company has a market capitalization of $302.67 billion, a PE ratio of 34.52, a PEG ratio of 2.76 and a beta of 0.18. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the business earned $2.22 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.